US 12,269,825 B2
Organic compounds
Sharon Mates, New York, NY (US); Peng Li, New Milford, NJ (US); Lawrence P. Wennogle, Hillsborough, NJ (US); and Robert Davis, San Diego, CA (US)
Assigned to INTRA-CELLULAR THERAPIES, INC., Bedminster, NJ (US)
Filed by INTRA-CELLULAR THERAPIES, INC., New York, NY (US)
Filed on Dec. 16, 2022, as Appl. No. 18/067,387.
Application 18/067,387 is a continuation of application No. 17/124,224, filed on Dec. 16, 2020, granted, now 11,560,382.
Application 17/124,224 is a continuation of application No. 16/786,240, filed on Feb. 10, 2020, granted, now 10,899,762, issued on Jan. 26, 2021.
Application 16/786,240 is a continuation of application No. 16/054,728, filed on Aug. 3, 2018, granted, now 10,597,394, issued on Mar. 4, 2020.
Application 16/054,728 is a continuation of application No. 15/301,912, granted, now 10,077,267, issued on Sep. 18, 2018, previously published as PCT/US2015/024340, filed on Apr. 3, 2015.
Claims priority of provisional application 61/975,610, filed on Apr. 4, 2014.
Prior Publication US 2023/0203037 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/16 (2006.01); A61K 31/4985 (2006.01); A61K 45/06 (2006.01); A61P 25/18 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); C07B 59/00 (2006.01); C07D 471/14 (2006.01)
CPC C07D 471/16 (2013.01) [A61K 31/4985 (2013.01); A61K 45/06 (2013.01); A61P 25/18 (2018.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01); C07B 59/002 (2013.01); C07D 471/14 (2013.01)] 15 Claims
 
1. A pharmaceutical composition comprising a compound of formula I:

OG Complex Work Unit Chemistry
wherein:
R1 is CH3;
R2 and R3 are each independently H or D;
R4 and R5 are each H;
provided that R2 and R3 are not both H,
and wherein D is deuterium;
in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier.